Tuesday 13 October 2026
Export ASMB’s income statement to Excel — free account
Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
20.65
2.12
−9.31%
Follow ASMB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 3 | 3 | — | — | — | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 6.31 | 3.43 | 2.98 | 0.91 | (3.29) | — | (8.44) | (9.38) | 1.06 |
P/S ratio |
— | 91.05 | 34.83 | 33.64 | 2.71 | 1.24 | — | 0.56 | 3.32 | 5.27 |
Altman Z″-Score (non-manufacturers) |
— | (0.54) | 2.37 | 3.04 | 3.24 | (2.68) | — | (16.91) | (21.02) | (1.34) |
P/FCF ratio |
— | 965.84 | 0.00 | 0.00 | 0.00 | 0.00 | — | 2.03 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (2.89) | (2.34) | (0.55) | (3.55) | — | — | — | — |
P/Operating CF |
— | (84.05) | (30.82) | (26.16) | (8.48) | (5.21) | — | 0.62 | (232.82) | 26.78 |
P/B ratio |
— | 7.26 | 2.45 | 1.97 | 0.89 | 0.60 | — | 1.11 | 2.84 | 1.84 |
Price to Tangible BV |
— | 11.49 | 3.05 | 2.32 | 1.08 | 0.79 | — | 0.00 | 0.00 | 2.31 |
EV/Sales |
— | 77.75 | 20.10 | 16.48 | (0.03) | (0.56) | — | (1.04) | (0.61) | 1.84 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.03 | 0.51 | — | 1.16 | 0.35 | 0.00 |
EV/Operating CF |
— | 376.99 | (4.58) | (3.13) | 0.03 | 0.49 | — | (3.72) | 0.34 | (3.24) |
EV/FCF |
— | 824.76 | (4.56) | (3.07) | 0.03 | 0.48 | — | (3.76) | 0.34 | (3.24) |
Quick Ratio |
7.44 | 9.06 | 11.94 | 11.35 | 8.91 | 9.14 | 5.68 | 3.32 | 2.34 | 5.11 |
Current Ratio |
7.52 | 9.13 | 12.05 | 11.57 | 9.19 | 9.59 | 5.95 | 3.41 | 2.42 | 5.22 |
Net Debt/EBITDA |
1.17 | 2.31 | 2.36 | 2.64 | 3.38 | 1.63 | 0.98 | 1.98 | 2.29 | 17.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.07 | 0.07 | 0.05 | 0.25 | 0.03 | 0.00 | 0.06 | 0.22 | 0.38 |
Operating CF/Net income |
0.79 | (0.04) | 0.72 | 0.86 | 1.01 | 0.72 | 0.91 | (0.37) | 1.27 | 6.71 |
Capex/Depreciation |
(1.84) | (3.95) | (0.82) | 1.25 | (0.69) | (0.05) | (0.16) | 0.20 | 0.01 | 0.03 |
| (44.57%) | (44.36%) | (56.06%) | (40.36%) | (24.19%) | (63.42%) | (74.00%) | (98.95%) | (107.92%) | (5.10%) | |
| (38.18%) | (32.02%) | (41.50%) | (32.12%) | (19.95%) | (54.75%) | (63.58%) | (51.32%) | (31.39%) | (3.25%) | |
ROIC |
(105.14%) | 0.00% | 0.00% | 0.00% | (167.54%) | (371.85%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(94.84%) | (38.75%) | (44.36%) | (37.53%) | (30.82%) | (93.24%) | (114.34%) | (64.49%) | (59.10%) | (2.97%) |
Average Days of Receivables |
— | 92.03 | 59.91 | 77.15 | 5.68 | 19.61 | 0.00 | 2.19 | 0.00 | 4.92 |
Research and Development Expense of Revenue |
0.00% | 490.35% | 491.36% | 537.22% | 135.04% | 1,095.68% | 0.00% | 682.67% | 196.12% | 89.64% |
Selling, General and Administrative Expense of Revenue |
0.00% | 188.72% | 235.06% | 206.22% | 46.85% | 460.19% | 0.00% | 319.82% | 63.14% | 27.12% |
Intangible Assets out of Total Assets |
0.42 | 0.25 | 0.16 | 0.12 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 95.37% | 192.41% | 128.79% | 27.63% | 83.74% | 0.00% | 71.46% | 10.94% | 6.47% |
Graham Net Nets |
— | 0.08 | 0.32 | 0.40 | 0.85 | 1.31 | — | 0.83 | 0.31 | 0.53 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (5.32%) | (17.69%) | (18.19%) | (28.94%) | (129.67%) | — | (133.26%) | (42.59%) | (2.18%) |
Free Cash Flow Yield |
— | 0.10% | (12.67%) | (15.94%) | (29.60%) | (94.87%) | — | 49.38% | (53.97%) | (10.79%) |
Revenue per Share |
0.00 | 6.10 | 7.79 | 7.30 | 26.81 | 1.73 | 0.00 | 1.57 | 4.75 | 6.45 |
Operating CF per Share |
(24.31) | 1.26 | (34.20) | (38.43) | (21.33) | (25.91) | (20.94) | 4.97 | (8.51) | (3.67) |
Capex per Share |
(0.10) | (0.58) | (0.18) | (0.71) | (0.16) | (0.62) | (0.03) | (0.05) | 0.00 | (0.01) |
Free Cash Flow per Share |
(24.41) | 0.67 | (34.38) | (39.14) | (21.49) | (26.53) | (20.96) | 4.92 | (8.52) | (3.67) |
Cash per Share |
36.91 | 81.12 | 114.82 | 125.28 | 73.33 | 40.67 | 22.71 | 28.46 | 18.66 | 22.13 |
Shareholders Equity per Share |
55.67 | 76.50 | 110.91 | 124.90 | 81.52 | 46.86 | 20.49 | 8.98 | 5.56 | 18.44 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
55.67 | 76.50 | 110.91 | 124.90 | 81.52 | 46.86 | 20.49 | 8.98 | 5.56 | 18.44 |
Free Cash Flow |
(35.03) | 1.00 | (65.30) | (85.62) | (63.43) | (95.63) | (84.56) | 22.51 | (51.14) | (41.16) |
Working Capital |
46.45 | 109.63 | 204.03 | 258.34 | 200.06 | 138.13 | 80.67 | 94.56 | 67.70 | 205.77 |
Capital Expenditures |
(0.15) | (0.86) | (0.34) | (1.55) | (0.47) | (2.24) | (0.10) | (0.23) | (0.03) | (0.07) |
Net Current Asset Value |
35.33 | 66.94 | 165.11 | 216.09 | 181.82 | 132.07 | 77.84 | 38.06 | 29.69 | 203.71 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.03 | 0.35 | — | 1.31 | 0.38 | 0.00 |
Capex to Sales |
0.00 | 0.10 | 0.02 | 0.10 | 0.01 | 0.36 | 0.00 | 0.03 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.37 | 0.25 | 0.74 | (0.68) | 0.42 | 37.48 | 0.88 | (2.95) | (12.43) | (10.03) |
Cash ROIC |
(26.37%) | 0.43% | (15.23%) | (15.65%) | (13.88%) | (30.31%) | (48.52%) | 13.14% | (35.17%) | (9.05%) |
Accounts Receivable Turnover |
— | 3.84 | 6.29 | 5.50 | 34.36 | 7.99 | 0.00 | 14.51 | 0.00 | 142.19 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 2.35 | 2.35 | 2.90 | 2.30 | 0.78 | 0.64 | 0.49 | — | 0.51 |
Average Payables |
1.87 | 2.25 | 2.91 | 2.71 | 3.16 | 3.63 | 2.58 | 1.48 | 0.52 | 0.88 |
Average Assets |
115.93 | 133.71 | 218.67 | 303.98 | 311.58 | 237.16 | 146.43 | 119.31 | 128.00 | 188.38 |
Average Common Equity |
99.31 | 96.50 | 161.89 | 241.94 | 256.90 | 204.75 | 125.80 | 61.88 | 37.23 | 120.06 |
Columns are period end dates